CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2009-07-24 | FROST PHILLIP MD ET AL 10% owner | Sale | −2,500 | $6.28 | $16K | 9,762,192 |
| 2009-07-24 | FROST PHILLIP MD ET AL 10% owner | Sale | −919 | $6.29 | $6K | 9,761,273 |
| 2009-07-07 | Almon Einat Brill VP, Product Development | Sale | −11,000 | $4.95 | $54K | 0 |
| 2009-07-07 | Almon Einat Brill VP, Product Development | Option exercise | +59,822 | $0.40 | $24K | 0 |
| 2009-07-07 | Almon Einat Brill VP, Product Development | Shares withheld for taxes | −4,822 | $4.95 | $24K | 0 |
| 2009-07-07 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −59,822 | 98,694 | ||
| 2009-07-07 | Maimon Yossi VP, Chief Financial Officer | Sale | −10,000 | $5.01 | $50K | 0 |
| 2009-07-07 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +62,217 | $0.97 | $60K | 0 |
| 2009-07-07 | Maimon Yossi VP, Chief Financial Officer | Shares withheld for taxes | −12,217 | $4.95 | $60K | 0 |
| 2009-07-07 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −62,217 | 391,431 | ||
| 2009-07-06 | Almon Einat Brill VP, Product Development | Sale | −44,000 | $5.13 | $226K | 0 |
| 2009-07-06 | Shaaltiel Yoseph Executive VP, R&D | Sale | −80,000 | $5.13 | $410K | 1,383,754 |
| 2009-07-06 | Shaaltiel Yoseph Executive VP, R&D | Sale | −20,000 | $4.95 | $99K | 1,363,754 |
| 2009-07-06 | Maimon Yossi VP, Chief Financial Officer | Sale | −40,000 | $5.13 | $205K | 0 |
| 2009-05-18 | Almon Einat Brill VP, Product Development | Option exercise | +44,707 | $0.40 | $18K | 44,707 |
| 2009-05-18 | Almon Einat Brill VP, Product Development | Shares withheld for taxes | −4,707 | $3.79 | $18K | 40,000 |
| 2009-05-18 | Almon Einat Brill VP, Product Development | Sale | −40,000 | $4.00 | $160K | 0 |
| 2009-05-18 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −44,707 | 158,516 | ||
| 2009-05-18 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +40,348 | $0.97 | $39K | 40,348 |
| 2009-05-18 | Maimon Yossi VP, Chief Financial Officer | Shares withheld for taxes | −10,348 | $3.79 | $39K | 30,000 |
Page 28 of 33 · 654 trades